-
Speaker: Dr. Lindsey A. George
FVIII Expression Durability after AAV Gene Transfer for Hemophilia A: The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor FVIII expression that predictably alleviates bleeding with the use of the lowest possible vector dose. Join Dr. Lindsey A. George as he presents the latest update on FVIII Expression Durability after AAV Gene Transfer for Hemophilia A and shares his recent lab discovery.
NBDF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn about the latest in research, breakthrough developments, and more.